This inventor holds 1 USPTO granted patent. Top assignee: S&k Therapeutics. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Yoojin Oh: Innovator in Therapeutic Compounds
Introduction
Yoojin Oh is a prominent inventor based in Daegu, South Korea. He has made significant contributions to the field of therapeutic agents, particularly in the area of autoimmune diseases. His innovative work has led to the development of small-molecule compounds that target endosomal toll-like receptors.
Latest Patents
Yoojin Oh holds a patent for "Small-molecule compounds for controlling endosomal toll-like receptors and therapeutic agent for autoimmune diseases using same." This patent describes antagonistic small-molecule compounds that inhibit endosomal Toll-like receptors (TLRs), specifically targeting TLR3, TLR7, TLR8, and TLR9 signaling pathways. The novel compound has shown promising results in a systemic lupus erythematosus animal model, effectively preventing TNF-α secretion and inhibiting the production of inflammatory cytokines. This suggests its potential utility in treating TLR-associated autoimmune diseases, inflammatory diseases, and viral diseases.
Career Highlights
Yoojin Oh is currently associated with S&K Therapeutics, where he continues to advance his research and development efforts. His work is characterized by a strong focus on innovative therapeutic solutions that address critical health challenges.
Collaborations
Yoojin collaborates with notable colleagues, including Doohyun Lee and Sangdun Choi, who contribute to his research endeavors and help drive forward the mission of S&K Therapeutics.
Conclusion
Yoojin Oh's contributions to the field of therapeutic compounds highlight his role as an influential inventor. His innovative approaches to treating autoimmune diseases through small-molecule compounds demonstrate the potential for significant advancements in medical science.